iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek(University of Cologne), Bruce D. Cheson(Georgetown University), Daniel Catovsky(Institute of Cancer Research), Federico Caligaris‐Cappio(Vita-Salute San Raffaele University), Guillermo Dighiero(Institut Pasteur de Montevideo), Hartmut Döhner(Universität Ulm), Peter Hillmen(St James's University Hospital), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Emili Montserrat(Universitat de Barcelona), Nicholas Chiorazzi(Feinstein Institute for Medical Research), Stephan Stilgenbauer(Universität Ulm), Kanti R. Rai(Feinstein Institute for Medical Research), John C. Byrd(The Ohio State University), Barbara Eichhorst(University of Cologne), Susan O’Brien(University of California, Irvine), Tadeusz Robak(Medical University of Lodz), John F. Seymour(The Royal Melbourne Hospital), Thomas J. Kipps(University of California San Diego)
Blood
March 14, 2018
Cited by 1,675Open Access
Full Text

Abstract

The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.


Related Papers

No related papers found

Powered by citation graph analysis